Navigation Links
Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials

of tolvaptan.

In each short-term study, significantly more patients in the tolvaptan groups reported improvements in dyspnea (difficult breathing) on the first inpatient day compared with the placebo groups (p less than 0.001 in both study A and study B). Significantly more patients in the tolvaptan group had improvements in investigator-assessed pedal edema at inpatient day seven or discharge in study B (p equal to 0.020), while the difference between groups in study A did not reach statistical significance (p equal to 0.070).(1)

Long-Term Trial: Pre-Specified Secondary Endpoints

The secondary endpoints of the composite of cardiovascular death or cardiovascular hospitalization, the incidence of cardiovascular mortality, and the incidence of clinical worsening of heart failure did not differ between the two treatment groups. A larger number of cardiovascular hospitalizations were adjudicated as due to myocardial infarction in the placebo group (n equal to 42) than in the tolvaptan group (n equal to 25) and a larger number were adjudicated as due to stroke in the tolvaptan group (n equal to 45) than in the placebo group (n equal to 24).(2)

The long-term tolvaptan data were consistent with those reported in the short-term clinical studies. Specifically, long-term tolvaptan treatment significantly reduced participants' body weight at day one (p less than 0.001) compared to placebo and the difference in body weight numerically favored tolvaptan through week 56. The long-term trial also documented that tolvaptan patients who enrolled with hyponatremia (serum sodium less than 134 mEq/L) exhibited significantly greater corrections in serum sodium at day seven or discharge, if earlier, (p less than 0.001) and the effect was maintained through 40 weeks of treatment.(2)

"The EVEREST data suggest that the mechanism of action of tolvaptan may represent a new therapeutic strategy that could provide symptomatic improvement for short-term care of
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
2. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
3. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
4. Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
5. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
6. Surfaxin (Lucinactant) Long-Term Survival Advantage vs. Comparators Published in Pediatrics
7. Long-Term Extension of Ulcerative Colitis Study Shows Remicade Responders Maintained Improvement Through Two Years of Follow-Up
8. New Long-Term Data Analyses for Bifeprunox Show Favorable Effects Versus Placebo in Stabilized Patients with Schizophrenia
9. Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing Sustained Safety and Significant Reductions in Repeat Procedures
10. Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes for Moderate-Release Paclitaxel-Eluting Stent at Four Years
11. UCB Presents Long-Term CImzia Data in Crohns Disease
Post Your Comments:
(Date:2/26/2015)... February 26, 2015 The ... Bottle washer, Filler, Capper, Blow molder, Shrink wrapper), ... (Still, Flavored, Sparkling) & Region - Trends & ... segments the bottled water processing market with analyses ... terms of value. It also identifies the driving ...
(Date:2/26/2015)... 2015 People with psoriasis and their ... participate in research that aims to improve treatments ... psoriasis registry begins recruiting patients in 2015. ... National Psoriasis Foundation and Corrona, LLC, will initially ... new biologic medication by Novartis Pharmaceuticals for moderate-to-severe ...
(Date:2/26/2015)... Pharma, Inc. (Nasdaq: MEIP ), an oncology company ... announced today that Daniel P. Gold , Ph.D., President ... Company 35 th Annual Health Care Conference on Wednesday, ... Boston Marriott Copley Place. A live webcast of the presentation ... be available approximately one hour after the presentation. ...
Breaking Medicine Technology:Bottled Water Processing Market Worth $2,106.5 Million by 2019 2Bottled Water Processing Market Worth $2,106.5 Million by 2019 3Bottled Water Processing Market Worth $2,106.5 Million by 2019 4First independent U.S. psoriasis registry will track drug safety and effectiveness 2First independent U.S. psoriasis registry will track drug safety and effectiveness 3MEI Pharma to Present at Cowen and Company Health Care Conference 2MEI Pharma to Present at Cowen and Company Health Care Conference 3
(Date:2/27/2015)... Maryland (PRWEB) February 27, 2015 Dr. James ... shocked by new data saying that 6 people die every ... created a new eBook to address the problem and help ... Update on Alcohol has answers to the following questions:, ... , Do you know what binge drinking is? ...
(Date:2/27/2015)... Aliso Viejo, CA (PRWEB) February 27, 2015 ... of TransFold Volume 3 for Final Cut Pro X. , ... presets built exclusively for FCPX users.” Said Christina ... endless possibilities to any Final Cut Pro X editor.” , ... for Final Cut Pro X. The user can decide to ...
(Date:2/26/2015)... Dallas, Texas (PRWEB) February 27, 2015 ... Industry is a professional and in-depth study on the ... with a focus on the Chinese situation. , ... PEIXING, Enox, SHANGDONG ZOUPING, Hualun, Jiangsu Yuanyang, ZHENGZHOU TONGLI, ... Roma Chemicals and Jain & Jain. , The report ...
(Date:2/26/2015)... 2015 Yisrayl Hawkins, Pastor and Overseer at ... new letter that he says contains absolute proof that the ... starts by showing what the plan, or purpose for mankind ... mankind, which has a beginning and an end. , ... who will believe and walk in His Righteousness, and who ...
(Date:2/26/2015)... Marking its fifth successful year of business, ... announced the development of a new and improved UV-Aid light ... this spring. UV-Aid is a unique and patent pending technology ... in areas of the body susceptible to infection. UVA light ... the daily dose of UV-Aid is equivalent to less than ...
Breaking Medicine News(10 mins):Health News:6 People Die Each Day From Alcohol Poisoning, new Essential Guide to Prescription Drugs eBook seeks to prevent interactions and deaths 2Health News:Announcing a New TransFold Transition Pack from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:World Benzoyl Peroxide Market Forecast Report 2015-2020 Now at Available DeepResearchReports.com 2Health News:World Benzoyl Peroxide Market Forecast Report 2015-2020 Now at Available DeepResearchReports.com 3Health News:Yisrayl Hawkins Says There is Only One Place Shown in Scripture to Achieve Salvation and Shows Proof in New Letter 2Health News:UV Technologies, LLC Developing New More Effective UV-Aid for Flu and Cold Prevention 2
... LifeCare Holdings, Inc. (the,"Company") today announced its operating results ... Our net patient service revenue increased by $6.4 million, ... $88.8 million from $82.4 million,for the comparable period in 2007. ... than the same period in 2007., The increase in ...
... Patient safety in hospitals focus of 48 NQF-endorsed ... patient,safety remains a major hurdle in the United ... voluntary consensus standards focused on,measuring the performance of ... readmission, and prevention and care,of venous thromboembolism., ...
... - QLT Inc. (NASDAQ: QLTI; TSX:,QLT) announced today that ... the land and building comprising its corporate headquarters and ... with the closing of the transaction, QLT will enter ... continue its operations., "We are very pleased that ...
... appear to help quality of life for lung cancer ... -- Adding chemotherapy to other treatments being giving to ... asbestos exposure, does not appear to improve either survival ... which is usually fatal, is a cancer of the ...
... Corporation,("Select") today announced results for its first quarter ... ended March 31, 2008, net operating revenues,increased 17.4% ... the same,quarter, prior year. Income from operations decreased ... the same quarter, prior year. Net income,decreased 47.9% ...
... Governor Paterson,s leadership in proposing prescription,drug marketing reform ... AARP strongly believes,New York has a paramount interest ... address the undue influence that,pharmaceutical companies have over ... but the treatment they receive., The reforms ...
Cached Medicine News:Health News:LifeCare Holdings, Inc. Announces First Quarter Results 2Health News:LifeCare Holdings, Inc. Announces First Quarter Results 3Health News:LifeCare Holdings, Inc. Announces First Quarter Results 4Health News:LifeCare Holdings, Inc. Announces First Quarter Results 5Health News:LifeCare Holdings, Inc. Announces First Quarter Results 6Health News:LifeCare Holdings, Inc. Announces First Quarter Results 7Health News:LifeCare Holdings, Inc. Announces First Quarter Results 8Health News:LifeCare Holdings, Inc. Announces First Quarter Results 9Health News:National Quality Forum Endorses Consensus Standards for Quality of Hospital Care 2Health News:National Quality Forum Endorses Consensus Standards for Quality of Hospital Care 3Health News:National Quality Forum Endorses Consensus Standards for Quality of Hospital Care 4Health News:National Quality Forum Endorses Consensus Standards for Quality of Hospital Care 5Health News:QLT Inc. announces agreement for sale of real estate 2Health News:QLT Inc. announces agreement for sale of real estate 3Health News:Chemo for Mesothelioma Offers Limited Survival Benefits 2Health News:Select Medical Corporation Announces Results for First Quarter Ended March 31, 2008 2Health News:Select Medical Corporation Announces Results for First Quarter Ended March 31, 2008 3Health News:Select Medical Corporation Announces Results for First Quarter Ended March 31, 2008 4Health News:Select Medical Corporation Announces Results for First Quarter Ended March 31, 2008 5Health News:Select Medical Corporation Announces Results for First Quarter Ended March 31, 2008 6Health News:Select Medical Corporation Announces Results for First Quarter Ended March 31, 2008 7Health News:Select Medical Corporation Announces Results for First Quarter Ended March 31, 2008 8Health News:Select Medical Corporation Announces Results for First Quarter Ended March 31, 2008 9Health News:AARP Statement on Governor's Bill for Prescription Drug Marketing Reform and Transparency 2
This modular benchtop fume hood ventilates and purifies chemical fumes, allowing safe indoor release of exhaust. Bonded charcoal filters remove most organic contaminants. Options include final HEPA f...
... mounts on a standard ring stand rod ... 1/2" ) mounting rod. The 14cm (5 ... the source of fumes. A top connector ... to an aspirator or vacuum source. Tubing, ...
... These corrosion proof polypropylene exhaust hoods are ... of tanks and draw a stream of ... away from the operator. Other sizes and ... lateral, and double-slot are available on special ...
... The Benchtop Fume Hood is an ... installations in which a number of fume ... schools, junior colleges and universities. Features include ... polyethylene with rounded inside corners for easy ...
Medicine Products: